Background: Diabetic retinopathy (DR) is a major cause of blindness globally. Sodium Glucose Cotransporter-2 (SGLT2) inhibitors have been demonstrated to exert cardiorenal protection in patients with diabetes. However. their potential beneficial effect on DR is less well studied. https://www.markymarkscott.com/product-category/7-34-7gc/